Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New Variant Tracking Option Expands Molecular Residual Disease Monitoring

By LabMedica International staff writers
Posted on 22 Oct 2026

Molecular residual disease (MRD) testing can detect traces of cancer that persist after treatment or emerge during recurrence. More...

Because circulating tumor DNA (ctDNA) may be present at very low levels, residual or recurrent disease can be difficult to assess with conventional measures alone. A newly launched test option now adds supplemental tracking of clinically relevant resistance and targetable variants during MRD monitoring.

Personalis, Inc. (Fremont, CA, USA) has launched optional Real-Time Variant Tracker supplemental results within the NeXT Personal molecular residual disease test report. The feature tracks clinically relevant resistance and therapeutically targetable variants over time during NeXT Personal testing. It includes variants with established clinical significance, including associations with FDA-approved therapies and recommendations in National Comprehensive Cancer Network (NCCN) guidelines. The supplemental results became commercially available beginning October 20, 2026.

Real-Time Variant Tracker adds longitudinal variant monitoring as cancer biology evolves. Personalis describes its highly sensitive assays as combining tumor-and-normal profiling with proprietary algorithms to provide genomic insights over time. Its products are designed to support early detection of MRD and recurrence, guide targeted therapy selection through comprehensive genomic profiling, and inform biomarker strategies for drug development.

The feature was first introduced through an Early Access Program in January 2026, allowing select clinical and academic users to incorporate the supplemental results into real-world clinical practice. The commercial launch now makes Real-Time Variant Tracker available as an optional supplemental component of the NeXT Personal test report.

“The ultrasensitivity of NeXT Personal allows us to detect very low levels of ctDNA, which can be particularly important when we’re monitoring patients whose disease may be difficult to assess through conventional measures alone. I see opportunities for highly sensitive ctDNA testing in settings including historically challenging tumor types such as earlier-stage breast and lung cancers. And as we follow patients over time, we’re not only asking whether disease is present, but also how the biology of the cancer may be changing. Real-Time Variant Tracker follows those changes over the course of NeXT Personal testing,” said Dr. Leo Shunyakov, M.D., medical oncologist and hematologist at Central Care Cancer Center.

Related Links
Personalis


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.